A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 74,500 shares of NVCT stock, worth $543,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,500
Previous 61,700 20.75%
Holding current value
$543,850
Previous $506,000 6.92%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$5.98 - $8.25 $76,544 - $105,600
12,800 Added 20.75%
74,500 $471,000
Q1 2024

May 13, 2024

BUY
$6.69 - $11.0 $66,231 - $108,900
9,900 Added 19.11%
61,700 $506,000
Q4 2023

Feb 13, 2024

BUY
$7.85 - $11.78 $207,240 - $310,992
26,400 Added 103.94%
51,800 $432,000
Q3 2023

Nov 14, 2023

SELL
$12.89 - $16.29 $141,790 - $179,190
-11,000 Reduced 30.22%
25,400 $327,000
Q2 2023

Aug 11, 2023

BUY
$12.62 - $18.4 $459,368 - $669,760
36,400 New
36,400 $581,000

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $107M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.